Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Gastrointestinal 4Thoracic 3Sarcoma 3Plasma cell 2Gynecologic 2Genitourinary 2Breast 2Other neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Prostatic Neoplasms 697Urinary Bladder Neoplasms 256Carcinoma, Renal Cell 190Kidney Neoplasms 94Neoplasms 72Carcinoma, Transitional Cell 69Breast Neoplasms 66Lung Neoplasms 38Ovarian Neoplasms 37Melanoma 37Colorectal Neoplasms 37Stomach Neoplasms 36Non-Muscle Invasive Bladder Neoplasms 35Neoplasm Metastasis 33Pancreatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 29Recurrence 26Colonic Neoplasms 25Uterine Cervical Neoplasms 20Urologic Neoplasms 20Testicular Neoplasms 20Esophageal Neoplasms 20Liver Neoplasms 18Head and Neck Neoplasms 18Disease 18Wilms Tumor 17Carcinoma, Hepatocellular 17Endometrial Neoplasms 16Sarcoma 15Prostatic Hyperplasia 15

Interventions

pazopanib 1glucarpidase 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Drug-Related Side Effects and Adverse Reactions × Genitourinary × Clear all
NCT05899751 2024-05-10

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

BTG International Inc.

Unknown
1,000 enrolled
GenitourinaryOther hematologic neoplasmSarcoma

Osteosarcoma, Water Intoxication, Hematologic Neoplasms, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions

NCT02324803 2014-12-24

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Southern China Urology Cancer Consortium

Phase 2 Unknown
86 enrolled
Genitourinary

Carcinoma, Renal Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡